Evaluating a City-Hospital Program for Early Liver Fibrosis Detection in Primary Care Using Fibroscan in Grenoble

What this Trial Is About

Researchers are studying liver fibrosis, a condition linked to cirrhosis and liver cancer, which causes many deaths in France. The study focuses on evaluating a care pathway designed to improve early detection and management of liver fibrosis in patients at risk, particularly in primary care settings. This pathway aims to help manage risk factors and ensure appropriate specialist referrals, addressing challenges such as limited awareness and access to Fibroscan40, a non-invasive liver fibrosis test. The care pathway involves screening patients aged 18 and older who have a Fibroscan40 result of 8 kPa or higher, indicating significant liver fibrosis. These tests are requested by primary care practitioners based on screening recommendations using the FIB-4 score. The study does not alter patient care but collects data and conducts telephone interviews to evaluate how well risk factors are managed and if patients are referred to specialists as needed. Participants will undergo their usual care, including Fibroscan40 testing, and researchers will collect information on management of fibrosis risk factors, patient satisfaction, and social factors related to liver fibrosis risk over up to 30 months. The study measures include the frequency of risk factors, specialist consultation rates, and overall adherence to the care pathway. No additional procedures are required beyond routine care and data collection for evaluation.

City-Hospital Collaboration for Early Detection of Liver Fibrosis in Primary Care: A Secondary Prevention Project in the Grenoble Health Area